Alliancebernstein L.P. Immunity Bio, Inc. Transaction History

Alliancebernstein L.P.

$278 Billion
Q2 2024

A detailed history of Alliancebernstein L.P. transactions in Immunity Bio, Inc. stock. As of the latest transaction made, Alliancebernstein L.P. holds 205,530 shares of IBRX stock, worth $739,908. This represents 0.0% of its overall portfolio holdings.

Number of Shares

205,530

Previous 178,930 14.87%

Holding current value

$739,908

Previous $960,000 35.21%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$4.82 - $9.15 $128,212 - $243,390	26,600 Added 14.87%	205,530 $1.3 Million
Q1 2024 May 14, 2024	SELL	$3.23 - $6.17 $342,380 - $654,020	-106,000 Reduced 37.2%	178,930 $960,000
Q4 2023 Feb 14, 2024	SELL	$1.25 - $5.21 $13,037 - $54,340	-10,430 Reduced 3.53%	284,930 $1.43 Million
Q3 2023 Nov 14, 2023	SELL	$1.29 - $3.1 $4,708 - $11,315	-3,650 Reduced 1.22%	295,360 $499,000
Q2 2023 Aug 15, 2023	BUY	$1.53 - $6.41 $72,601 - $304,167	47,452 Added 18.86%	299,010 $831,000
Q1 2023 May 15, 2023	BUY	$1.35 - $4.78 $34,830 - $123,324	25,800 Added 11.43%	251,558 $457,000
Q2 2022 Aug 15, 2022	BUY	$2.68 - $6.14 $106,396 - $243,758	39,700 Added 21.34%	225,758 $840,000
Q1 2022 May 13, 2022	BUY	$5.05 - $7.53 $179,275 - $267,315	35,500 Added 23.58%	186,058 $1.04 Million
Q4 2021 Feb 14, 2022	BUY	$5.67 - $10.18 $323,518 - $580,850	57,058 Added 61.02%	150,558 $915,000
Q3 2021 Nov 10, 2021	SELL	$9.17 - $14.24 $63,273 - $98,256	-6,900 Reduced 6.87%	93,500 $911,000
Q2 2021 Jul 30, 2021	BUY	$13.41 - $22.4 $732,186 - $1.22 Million	54,600 Added 119.21%	100,400 $1.43 Million
Q1 2021 May 06, 2021	BUY	$12.83 - $42.25 $587,614 - $1.94 Million	45,800 New	45,800 $1.09 Million

Others Institutions Holding IBRX

# of Institutions

216

Shares Held

63.3M

Call Options Held

1.43M

Put Options Held

4.12M

View Full List

About ImmunityBio, Inc.

Ticker IBRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 400,304,000
Market Cap $1.44B
Description
ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The com...

More about IBRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Alliancebernstein L.P., based on Form 13F filings with the SEC.

News

Stay updated on Alliancebernstein L.P. with notifications on news.

Account

Alliancebernstein L.P. Immunity Bio, Inc. Transaction History